[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341393-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341393-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","bioinformatics-design-of-a-peptide-vaccine-containing-sarcoma-antigen-ny-sar-35-epitopes-against-breast-cancer-and-evaluation-of-its-immunological-function-in-balbc-mouse-model","Bioinformatics design of a peptide vaccine containing sarcoma antigen NY-SAR-35 epitopes against breast cancer and evaluation of its immunological function in BALB/c mouse model","","Cancer vaccine development is a core goal in medical biotechnology and immunology. This study used bioinformatics to design a peptide vaccine targeting the NY-SAR-35 cancer/testis antigen and evaluated immunological function in BALB/c mice. Antigen-specific IgG levels were measured by ELISA, while IFN-γ, IL-4, and granzyme B were quantified from cultured splenocyte supernatants. The final AAY-linked T-epitope construct showed strong antigenicity, non-allergenicity, non-toxicity, and stability, with activity supported by MHC interactions and energy analyses. Formulation with incomplete Freund’s adjuvant markedly increased IgG and cytokine/granzyme secretion, alongside higher lymphocyte proliferation, indicating a robust immune response. Human clinical trials are needed to confirm efficacy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/bioinformatics-design-of-a-peptide-vaccine-containing-sarcoma-antigen-ny-sar-35-epitopes-against-breast-cancer-and-evaluation-of-its-immunological-function-in-balbc-mouse-model/341393/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/bioinformatics-design-of-a-peptide-vaccine-containing-sarcoma-antigen-ny-sar-35-epitopes-against-breast-cancer-and-evaluation-of-its-immunological-function-in-balbc-mouse-model/341393.png","ImageObject",300,407,{"name":42,"@type":43},"Noah","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which antigen and epitopes were targeted to design the peptide vaccine?","Question",{"text":63,"@type":64},"The vaccine was designed to target the NY-SAR-35 cancer/testis antigen and to include two T-lymphocyte epitopes linked by the AAY linker.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the immunological effects of the vaccine evaluated in BALB/c mice?",{"text":68,"@type":64},"Peptide-specific IgG levels were measured in serum by ELISA, and IFN-γ, IL-4, and granzyme B levels were assessed in the supernatant of cultured splenocytes. Lymphocyte proliferation was also compared with a control group.",{"name":70,"@type":61,"acceptedAnswer":71},"What key immunological outcomes did the study report after vaccine plus adjuvant administration?",{"text":72,"@type":64},"Administration with incomplete Freund’s adjuvant increased IgG and significantly elevated IFN-γ, IL-4, and granzyme B secretion, along with higher lymphocyte proliferation versus the control group.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341393,1790195711,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","PLOS ONE  \nOPEN ACCESS  \nCitation: Samman N, Mohabatkar H, Behbahani M, Ganjlikhani Hakemi M (2024) Bioinformatics design of a peptide vaccine containing sarcoma antigen NY-SAR-35 epitopes against breast cancer and evaluation of its immunological function in BALB/c mouse model. PLoS ONE 19(6):  \ne0306117 . [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0306117  \nEditor: Wenping Gong, 8th Medical Center of Chinese PLA General Hospital, CHINA  \nReceived: January 21, 2024  \nAccepted: June 10, 2024  \nPublished: June 26, 2024  \nCopyright: © 2024 Samman et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData Availability Statement: All relevant data are within the manuscript and its Supporting information files.  \nFunding: The author(s) received no specific funding for this work.  \nCompeting interests: The authors have declared that no competing interests exist.  \nRESEARCH ARTICLE  \nBioinformatics design of a peptide vaccine containing sarcoma antigen NY-SAR-35 epitopes against breast cancer and evaluation of its immunological function in BALB/c mouse model  \nNourSamman1, Hassan Mohabatkar1 *, Mandana Behbahani1, Mazdak Ganjlikhani Hakemi2,3  \n1 Department of Biotechnology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran, 2 Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran, 3 Regenerative and Restorative Medicine Research Center (REMER), Research Institute for Health Sciences and Technologies (SABITA), Istanbul Medipol University, Istanbul, Turkey  \n* [h.mohabatkar@ast.ui.ac.ir](h.mohabatkar@ast.ui.ac.ir)  \nAbstract  \nThe development of a cancer vaccine has become an essential focus in the field of medical biotechnology and immunology. In our study, the NY-SAR-35 cancer/testis antigen was targeted to design a novel peptide vaccine using bioinformatics tools, and BALB/c mice were used to evaluate the vaccine’s immunological function. This evaluation involved assessing peptide-specific IgG levels in the serum via ELISA and measuring the levels of IFN-γ , IL-4, and granzyme B in the supernatant of cultured splenocytes. The final vaccine construct consisted of two T lymphocyte epitopes linked by the AAY linker. This construct displayed high antigenicity, non-allergenicity, non-toxicity, stability, and ability to induce IFN-γ and IL-4 . It showed stable dynamics with both human MHC-I and II molecules, as well as mouse MHCII molecules, and revealed strong Van der Waals and electrostatic energies. Emulsifying our peptide vaccine in incomplete Freund’s adjuvant resulted in a remarkable increase in the levels of IgG. The splenocytes of mice that received the combination of peptide and adjuvant displayed a noteworthy increase in IFN-γ , IL-4, and granzyme B secretion. Additionally, their lymphocytes exhibited higher proliferation rates compared to the control group. Our data demonstrated that our vaccine could stimulate a robust immune response, making it a promising candidate for cancer prevention. However, clinical trials are necessary to assess its efficacy in humans.  \nIntroduction  \nBreast cancer is the most prevalent form of cancer among women, exerting a large influence on the global number of cancer deaths [ 1] . Malignant transformation of normal mammary  \ncells leads to the development of breast tumors, characterized by uncontrolled growth, proliferation, and invasion of cells [2] . Despite the use of radiotherapy, chemotherapy, and surgery for breast cancer treatment, patient prognosis remains unsatisfactory, particularly in those with metastatic disease [3] . Furthermore, the effectiveness of these therapies is limited by their side effects. As a result, there has been a growing interest in immunotherapy, specifically cancer vacci","cbCaigKuccVPKbNe","https://ap.wps.com/l/cbCaigKuccVPKbNe","pdf",4337261,32,"English","# Abstract\n# Introduction\n## Breast cancer background\n## Cancer vaccines and categories\n## Tumor antigens and CTAs\n## NY-SAR-35 antigen overview","[{\"question\":\"Which antigen and epitopes were targeted to design the peptide vaccine?\",\"answer\":\"The vaccine was designed to target the NY-SAR-35 cancer/testis antigen and to include two T-lymphocyte epitopes linked by the AAY linker.\"},{\"question\":\"How were the immunological effects of the vaccine evaluated in BALB/c mice?\",\"answer\":\"Peptide-specific IgG levels were measured in serum by ELISA, and IFN-γ, IL-4, and granzyme B levels were assessed in the supernatant of cultured splenocytes. Lymphocyte proliferation was also compared with a control group.\"},{\"question\":\"What key immunological outcomes did the study report after vaccine plus adjuvant administration?\",\"answer\":\"Administration with incomplete Freund’s adjuvant increased IgG and significantly elevated IFN-γ, IL-4, and granzyme B secretion, along with higher lymphocyte proliferation versus the control group.\"}]","Bioinformatics design of a peptide vaccine containing sarcoma antigen NY-SAR-35 epitopes against breast cancer and evaluation of its immunological function in BALB/c mouse model | PDF",1790041726,81,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f57fc9a7274aa1f6e65c36a10f6e5de.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/620c937d17520d84dbf1ccc90cdb9300.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e72c01051590eb98ed37c3cb5a58b7bc.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04a07fa8e26354ba37da63ed827de0dd.webp",980,1268]